AstraZeneca snips IL-12 candidate from pipeline as it sharpens I/O focus
Tipping its hand as part of its quarterly R&D update, AstraZeneca reported it has dropped two early-stage cancer drugs and a mid-stage candidate for chronic obstructive pulmonary disease, while also ditching some trials for Fasenra and an experimental IL-33 antibody.
The decision to discard an IL-12 therapy that works by delivering an IL-12 transgene within an oncolytic virus comes just days after Bristol Myers Squibb announced it’s handing back an IL-12 candidate to Dragonfly. But according to AstraZeneca, it’s all about prioritizing the pipeline.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.